Insulin Degludec/Insulin Aspart Administered Once Daily at Any Meal, With Insulin Aspart at Other Meals Versus a Standard Basal-Bolus Regimen in Patients With Type 1 Diabetes: A 26-week, phase 3, randomized, open-label, treat-to-target trial

Lignende værker

• Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal–bolus treatment in people with Type 1 diabetes: 1–year results from a randomized clinical trial (BOOST (®) T1)
  af: Hirsch, I. B., et al.
  Udgivet: (2016)
• Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial
  af: Kumar, Ajay, et al.
  Udgivet: (2016)
• A Novel Insulin Combination of Insulin Degludec and Insulin Aspart Achieves a More Stable Overnight Glucose Profile than Insulin Glargine: Results from Continuous Glucose Monitoring in a Proof-of-Concept Trial
  af: Liebl, Andreas, et al.
  Udgivet: (2013)
• Efficacy and safety of once‐daily insulin degludec/insulin aspart compared with once‐daily insulin glargine in participants with Type 2 diabetes: a randomized, treat‐to‐target study
  af: Kumar, S., et al.
  Udgivet: (2016)
• Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes
  af: Thalange, Nandu, et al.
  Udgivet: (2015)